Researchers developed novel live‑attenuated vaccine candidates for Venezuelan equine encephalitis virus (VEEV) to address a persistent arboviral threat lacking a broadly licensed human vaccine. Preclinical data describe attenuation strategies and immunogenicity profiles intended to balance safety and durable protection. The report positions the candidates as potential tools for outbreak response and protection of at‑risk populations, including laboratory personnel. Given VEEV’s epidemic potential, the work seeks to fill a preparedness gap; authors emphasized further safety testing and regulatory work will be needed before emergency or general‑use deployment is considered.